PubMed · 2002 · 38 citations · 71 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyPharmacodynamicsPsychopharmacologyAntiemetic PharmacologyAnxiolytic PharmacotherapyHypnotic PharmacotherapyPregnancy PharmacologyAnxiolytic Use In PregnancyCytokine AdjuvantsDrug-induced TeratogenicityHypnotic Use In PregnancyMedication TeratogenicityPharmaceutical TeratogenicityTeratogenic Effects Of DrugsTherapeutic Uses
Thalidomide was first introduced to the market in Germany under the brand name of Contergan in 1956, as a non-barbiturate hypnotic, advocated to ensure a good nights sleep and to prevent morning sickness in pregnancy. It was advertised for its prompt action, lack of hangover, and apparent safety. It has been banned from the market since 1963 after it caused the worldwide teratogenic disaster: babies exposed to thalidomide in utero during the first 34-50 days of pregnancy were born with severe life-threatening birth defects. Despite its unfortunate history, thalidomide has attracted scientific interest again because of its recently discovered action against inflammatory diseases and cancer. Its broad range of biological activities stems from its ability to moderate cytokine action in cancer and inflammatory diseases. Early studies examined its anxiolytic, mild hypnotic, antiemetic, and adjuvant analgesic properties. Subsequently, thalidomide was found to be highly effective in managing the cutaneous manifestations of leprosy, being superior to Aspirin in controlling leprosy-associated fever. Recent research has shown promising results with thalidomide in patients with myeloma, myelodysplastic syndrome, a variety of infectious diseases, autoimmune diseases, cancer, and progressive body weight loss related to advanced cancer and AIDS. Here we review the history of its development, pharmacokinetics, metabolism, biologic effects, and the results of clinical trials conducted thus far. Further research in this field should be directed towards better understanding of thalidomide metabolism, its mechanism of action, and the development of less toxic and more active analogs.
71
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Noel Weidner, Joseph P. Semple, William R. Welch et al. · New England Journal of Medicine · 1991 · 5.7K citations
Medicine, Cancer Biology, Oncology +15
1994 Consensus Conference on Acute GVHD Grading.
Donna Przepiorka, Daniel Weisdorf, Peyton Martin et al. · PubMed · 1995 · 5.1K citations
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Seema Singhal, Jayesh Mehta, Raman Desikan et al. · New England Journal of Medicine · 1999 · 2.6K citations · Full text
Medicine, Hematology, Oncology +14
Thalidomide is an inhibitor of angiogenesis.
Robert J. D’Amato, Michael Loughnan, Evelyn Flynn et al. · Proceedings of the National Academy of Sciences · 1994 · 2.5K citations
Response criteria for phase II studies of supratentorial malignant glioma.
David R. Macdonald, T L Cascino, S. Clifford Schold et al. · Journal of Clinical Oncology · 1990 · 2.4K citations